Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares Repurchased
Ratios

Neurocrine Biosciences (NBIX) Receivables - Other (2019 - 2025)

Neurocrine Biosciences' Receivables - Other history spans 7 years, with the latest figure at $20.5 million for Q4 2025.

  • For Q4 2025, Receivables - Other rose 42.36% year-over-year to $20.5 million; the TTM value through Dec 2025 reached $20.5 million, up 42.36%, while the annual FY2025 figure was $20.5 million, 42.36% up from the prior year.
  • Receivables - Other reached $20.5 million in Q4 2025 per NBIX's latest filing, up from $14.4 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $20.5 million in Q4 2025 to a low of $2.2 million in Q4 2021.
  • Average Receivables - Other over 5 years is $6.8 million, with a median of $4.4 million recorded in 2023.
  • Peak YoY movement for Receivables - Other: crashed 40.54% in 2021, then surged 186.36% in 2024.
  • A 5-year view of Receivables - Other shows it stood at $2.2 million in 2021, then surged by 113.64% to $4.7 million in 2022, then skyrocketed by 138.3% to $11.2 million in 2023, then rose by 28.57% to $14.4 million in 2024, then surged by 42.36% to $20.5 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Receivables - Other are $20.5 million (Q4 2025), $14.4 million (Q4 2024), and $12.6 million (Q1 2024).